Loading...
  • Prophylaxis
  • Graft-versus-host disease prophylaxis: Patients receive tacrolimus IV continuously beginning on day -3 and then orally when tolerated, oral sirolimus on days -3 and -2, anti-thymocyte globulin IV over 4-8 hours on days -3 to 0, and methotrexate* IV on days 1, 3, and 6. (clinicaltrials.gov)
  • aplastic anemia
  • Grafalon® (formerly commercialized as ATG Fresenius), is a rabbit anti-human T-lymphocyte immunoglobulin, used as part of immunosuppressive regimens for the prevention of graft versus host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation or as immunosuppressive in the treatment of aplastic anemia (according to country-specific approved indications). (neovii.com)
  • Treatment
  • Treatment depends upon which type of myeloproliferative disorder is present, as well as the age and other health problems that the patient might have. (rightdiagnosis.com)
  • Since the leukemic process involving the kidney may respond favorably to treatment, a renal biopsy should be considered in any patient presenting with unexplained severe or evolving kidney disease. (dovepress.com)
  • I have additional clinical expertise in the treatment of post-stem cell transplant complications, such as graft-versus-host disease. (seattlecca.org)
  • Translational research projects explore the potential utility of these mutations as novel DNA biomarkers for improved disease detection, treatment outcome, survival and quality of life. (fredhutch.org)
  • Number of patients who die of treatment-related complications. (clinicaltrials.gov)
  • patients
  • Determine the efficacy of umbilical cord blood transplantation, as measured by durable neutrophil engraftment, in patients with malignant or nonmalignant hematological disease. (knowcancer.com)
  • Determine the disease-free survival and long-term survival in patients treated with this regimen. (knowcancer.com)
  • Patients are stratified according to disease group (malignant vs nonmalignant). (knowcancer.com)
  • Patients with malignant disease are further stratified according to quality of HLA match (1 or 2/6 vs 3/6 vs 4/6 vs 5/6 or 6/6), cell dose, and age. (knowcancer.com)
  • Patients are assigned to one of three conditioning regimens, depending on disease. (knowcancer.com)
  • study results are used to establish a diagnosis, stratify patients into prognostic groups, guide medical management, and monitor disease progression. (arupconsult.com)
  • Genes
  • To solve some confusing situation on TP53 nomenclature, an international consortium has joined forces with the Locus Reference Genomic (LRG) consortium to provide a stable reference sequence and a coordinate system for permanent and unambiguous reporting of disease-causing variants in genes related to any pathology. (atlasgeneticsoncology.org)
  • donors
  • Therefore It will test the efficacy of combining sirolimus, tacrolimus, antithymocyte globulin, and rituximab in preventing graft versus host disease in transplants from HLA Haploidentical and partially mismatched donors. (clinicaltrials.gov)
  • Vaccine
  • With the current 2-dose program, there is potential that these most severe outcomes of a vaccine-preventable disease could be eliminated. (aappublications.org)
  • severe
  • Monitoring severe outcomes of disease, such as hospitalizations and deaths, is an important component of evaluating the impact of the varicella vaccination program. (aappublications.org)